Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Philadelphia Chromosome 1Neoplasm, Residual 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1

Interventions

blinatumomab 16Cyclophosphamide 15fludarabine phosphate 8fludarabine 8Methotrexate 7Cytarabine 7Rituximab 6Vincristine 5Mercaptopurine 5Melphalan 4Daunorubicin 4obinutuzumab 3Whole-Body Irradiation 3Immunotherapy, Adoptive 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Doxorubicin 3Dexamethasone 3Asparaginase 3tisagenlecleucel 2thymoglobulin 2pegaspargase 2Vindesine 2Thioguanine 2Teniposide 2Stem Cell Transplantation 2Radiotherapy 2Prednisone 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × flumatinib × Lymphoid × Clear all
NCT04375683 2022-03-24

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Zhongda Hospital

Phase 3 Unknown
28 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡